Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial

Mosca, M., Arnaud, L., Askanase, A., Hobar, C., Becker, B., Singhal, S., Banerjee, S., Pomponi, S., Choi, J., & Strand, V. (2025). Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial. Lupus Science & Medicine, 12(1), e001517. https://doi.org/10.1136/lupus-2025-001517
Authors:
Marta Mosca
Laurent Arnaud
Anca Askanase
Coburn Hobar
Brandon Becker
Shalabh Singhal
Subhashis Banerjee
Samantha Pomponi
Jiyoon Choi
Vibeke Strand
Affiliated Authors:
Anca Askanase
Columbia Affiliation:
Subjects:
Lupus Erythematosus, Systemic (MeSH)
Protein Kinase Inhibitors (MeSH)
Author Keywords:
clinical trial
lupus erythematosus, systemic
patient reported outcome measures
quality of life
elink
Publication Type:
Article
Unique ID:
10.1136/lupus-2025-001517
PMID:
40451616
DOI:
10.1136/lupus-2025-001517
Journal:
Lupus Science and Medicine
Publication Date:
Data Source:
Web of Science
Source Link:
View Web of Science Record
View PubMed Record
View Scopus Record

Record Created: